Monte Rosa Therapeutics (GLUE) Equity Average (2023 - 2025)
Historic Equity Average for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $257.0 million.
- Monte Rosa Therapeutics' Equity Average rose 1948.0% to $257.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.0 million, marking a year-over-year increase of 1948.0%. This contributed to the annual value of $201.1 million for FY2024, which is N/A changed from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Equity Average of $257.0 million as of Q3 2025, which was up 1948.0% from $271.6 million recorded in Q2 2025.
- Monte Rosa Therapeutics' Equity Average's 5-year high stood at $271.6 million during Q2 2025, with a 5-year trough of $165.9 million in Q1 2024.
- In the last 3 years, Monte Rosa Therapeutics' Equity Average had a median value of $214.6 million in 2024 and averaged $217.1 million.
- Per our database at Business Quant, Monte Rosa Therapeutics' Equity Average plummeted by 1753.25% in 2024 and then surged by 5013.34% in 2025.
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Equity Average stood at $181.9 million in 2023, then increased by 17.76% to $214.2 million in 2024, then increased by 19.96% to $257.0 million in 2025.
- Its Equity Average was $257.0 million in Q3 2025, compared to $271.6 million in Q2 2025 and $249.0 million in Q1 2025.